2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD3
  5. CD3 Inhibitor

CD3 Inhibitor

CD3 Inhibitors (10):

Cat. No. Product Name Effect Purity
  • HY-P99033
    Mosunetuzumab
    		Inhibitor
    Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs).
  • HY-P99592
    Solitomab
    		Inhibitor 98.15%
    Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer.
  • HY-P99762
    Obrindatamab
    		Inhibitor 99.58%
    Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer.
  • HY-P9989
    Linvoseltamab
    		Inhibitor 99.71%
    Linvoseltamab is a bispecific antibody targeting to both BCMA (TNFRSF17) and CD3 epsilon. Linvoseltamab shows safety profile and encouraging efficacy in relapsed/refractory multiple myeloma (RRMM) models.
  • HY-P99814
    Pavurutamab
    		Inhibitor
    Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM).
  • HY-P99124
    Anti-Mouse CD3 Antibody (17A2)
    		Inhibitor
    Anti-Mouse CD3 Antibody is an anti-mouse CD3 IgG2b antibody inhibitor derived from the host Rat.
  • HY-P99802
    Pasotuxizumab
    		Inhibitor 98.02%
    Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).
  • HY-P99757
    Nivatrotamab
    		Inhibitor 99.40%
    Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma.
  • HY-P99776
    Plamotamab
    		Inhibitor
    Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20+ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo.
  • HY-P990095
    Vonsetamig
    		Inhibitor
    Vonsetamig is a humanised immunoglobulin G4-kappa, anti-TNFRSF17 and CD3E monoclonal antibody. Vonsetamig is an antineoplastic.